https://www.selleckchem.com/pr....oducts/ici-118551-ic
9 and 6.6 h) and elimination (mean half-life between 11.3 and 19.5 h) were assessed. The most common toxicity was myelosuppression. Higher palbociclib exposure was associated with grade 3/4 neutropenia and leukopenia. Dose limiting toxicities included grade 4 neutropenia and grade 3 thrombocytopenia and dehydration. No patients had an objective response to palbociclib therapy. Palbociclib was safely administered to children and adolescents at a dosage of 75mg/m for 21 consecutive days followed by seven days of rest in bot